Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib and Tamoxifen in Ovarian Cancer with Biochemical Recurrence
NCT05669768Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Countries
- 1
- Sponsor
- Sun Yat-sen University
- Modality
- Small Molecules
- Drugs
- pamiparib
- Conditions
- epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
01
Overview
Phase 2, open-label trial of pamiparib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who achieved NED/CR/PR after platinum chemotherapy and received at least 12 months of first-line PARPi maintenance, now presenting with biochemical recurrence (elevated CA125) without imaging evidence of recurrence.
04
Registry description
The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of pamiparib + tamoxifen regimen in epithelial ovarian cancer patients with biochemical recurrence during first-line PARPi maintenance therapy. The main questions it aims to answer are:
- Effect of the regimen on the reduction of CA125
- The delayed effect of treatment regimens on the patient's radiographic progression
Beyond the preview
Go deeper on NCT05669768.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669768.